Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Primary Objective Part 1 • Evaluate the safety of escalating dose of zalutumumab in combination with irinotecan in patients with colorectal cancer (CRC) who have failed previous standard chemotherapy and who have progressed during or within 6 months of stopping treatment with cetuximab. Part 2 • To investigate the efficacy of zalutumumab administered alone or in combination with irinotecan in patients with CRC who have failed previous standard chemotherapy and who have progressed during or within 6 months of stopping treatment with cetuximab.
Critère d'inclusion
- Refractory colorectal cancer